|
1
|
Folkman J: What is the evidence that
tumors are angiogenesis dependent? J Natl Cancer Inst. 82:4–6.
1990. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Ferrara N: Vascular endothelial growth
factor as a target for anticancer therapy. Oncologist. 9(Suppl 1):
2–10. 2004. View Article : Google Scholar
|
|
3
|
Hicklin DJ and Ellis LM: Role of the
vascular endothelial growth factor pathway in tumor growth and
angiogenesis. J Clin Oncol. 23:1011–1027. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Kerbel RS: Tumor angiogenesis. N Engl J
Med. 358:2039–2049. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Presta M, Dell’Era P, Mitola S, Moroni E,
Ronca R and Rusnati M: Fibroblast growth factor/fibroblast growth
factor receptor system in angiogenesis. Cytokine Growth Factor Rev.
16:159–178. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Turner N and Grose R: Fibroblast growth
factor signalling: from development to cancer. Nat Rev Cancer.
10:116–129. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
7
|
Hurwitz H, Fehrenbacher L, Novotny W,
Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S,
Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R and Kabbinavar F:
Bevacizumab plus irinotecan, fluorouracil, and leucovorin for
metastatic colorectal cancer. N Engl J Med. 350:2335–2342. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Cheng AL, Kang YK, Chen Z, Tsao CJ, Qin S,
Kim JS, Luo R, Feng J, Ye S, Yang TS, et al: Efficacy and safety of
sorafenib in patients in the Asia-Pacific region with advanced
hepatocellular carcinoma: a phase III randomised, double-blind,
placebo-controlled trial. Lancet Oncol. 10:25–34. 2009. View Article : Google Scholar
|
|
9
|
Diaz-Padilla I and Siu LL: Brivanib
alaninate for cancer. Expert Opin Investig Drugs. 20:577–586. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Huynh H, Ngo VC, Fargnoli J, Ayers M, Soo
KC, Koong HN, Thng CH, Ong HS, Chung A, Chow P, Pollock P, Byron S
and Tran E: Brivanib alaninate, a dual inhibitor of vascular
endothelial growth factor receptor and fibroblast growth factor
receptor tyrosine kinases, induces growth inhibition in mouse
models of human hepatocellular carcinoma. Clin Cancer Res.
14:6146–6153. 2008. View Article : Google Scholar
|
|
11
|
Marathe PH, Kamath AV, Zhang Y, D’Arienzo
C, Bhide R and Fargnoli J: Preclinical pharmacokinetics and in
vitro metabolism of brivanib (BMS-540215), a potent VEGFR2
inhibitor and its alanine ester prodrug brivanib alaninate. Cancer
Chemother Pharmacol. 65:55–66. 2009. View Article : Google Scholar
|
|
12
|
Sitter B, Lundgren S, Bathen TF, Halgunset
J, Fjosne HE and Gribbestad IS: Comparison of HR MAS MR
spectroscopic profiles of breast cancer tissue with clinical
parameters. NMR Biomed. 19:30–40. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Beckonert O, Coen M, Keun HC, Wang Y,
Ebbels TM, Holmes E, Lindon JC and Nicholson JK: High-resolution
magic-angle-spinning NMR spectroscopy for metabolic profiling of
intact tissues. Nat Protoc. 5:1019–1032. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Cheng LL, Burns MA, Taylor JL, He W,
Halpern EF, McDougal WS and Wu CL: Metabolic characterization of
human prostate cancer with tissue magnetic resonance spectroscopy.
Cancer Res. 65:3030–3034. 2005.PubMed/NCBI
|
|
15
|
Swanson MG, Zektzer AS, Tabatabai ZL,
Simko J, Jarso S, Keshari KR, Schmitt L, Carroll PR, Shinohara K,
Vigneron DB and Kurhanewicz J: Quantitative analysis of prostate
metabolites using 1H HR-MAS spectroscopy. Magn Reson
Med. 55:1257–1264. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Erb G, Elbayed K, Piotto M, Raya J,
Neuville A, Mohr M, Maitrot D, Kehrli P and Namer IJ: Toward
improved grading of malignancy in oligodendrogliomas using
metabolomics. Magn Reson Med. 59:959–965. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Rocha CM, Barros AS, Gil AM, Goodfellow
BJ, Humpfer E, Spraul M, Carreira IM, Melo JB, Bernardo J, Gomes A,
Sousa V, Carvalho L and Duarte IF: Metabolic profiling of human
lung cancer tissue by 1H high resolution magic angle
spinning (HRMAS) NMR spectroscopy. J Proteome Res. 9:319–332. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Sitter B, Bathen T, Hagen B, Arentz C,
Skjeldestad FE and Gribbestad IS: Cervical cancer tissue
characterized by high-resolution magic angle spinning MR
spectroscopy. MAGMA. 16:174–181. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Yang J, Kim JH, Im GH, Heo H, Yoon S, Lee
J, Lee JH and Jeon P: Evaluation of antiangiogenic effects of a new
synthetic candidate drug KR-31831 on xenografted ovarian carcinoma
using dynamic contrast enhanced MRI. Korean J Radiol. 12:602–610.
2011. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Frenette C and Gish R: Targeted systemic
therapies for hepatocellular carcinoma: clinical perspectives,
challenges and implications. World J Gastroenterol. 18:498–506.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Miura H, Miyazaki T, Kuroda M, Oka T,
Machinami R, Kodama T, Shibuya M, Makuuchi M, Yazaki Y and Ohnishi
S: Increased expression of vascular endothelial growth factor in
human hepatocellular carcinoma. J Hepatol. 27:854–861. 1997.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Torimura T, Sata M, Ueno T, Kin M, Tsuji
R, Suzaku K, Hashimoto O, Sugawara H and Tanikawa K: Increased
expression of vascular endothelial growth factor is associated with
tumor progression in hepatocellular carcinoma. Hum Pathol.
29:986–991. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Moon WS, Rhyu KH, Kang MJ, Lee DG, Yu HC,
Yeum JH, Koh GY and Tarnawski AS: Overexpression of VEGF and
angiopoietin 2: a key to high vascularity of hepatocellular
carcinoma? Mod Pathol. 16:552–557. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Hsu PI, Chow NH, Lai KH, Yang HB, Chan SH,
Lin XZ, Cheng JS, Huang JS, Ger LP, Huang SM, Yen MY and Yang YF:
Implications of serum basic fibroblast growth factor levels in
chronic liver diseases and hepatocellular carcinoma. Anticancer
Res. 17:2803–2809. 1997.PubMed/NCBI
|
|
25
|
Mise M, Arii S, Higashituji H, Furutani M,
Niwano M, Harada T, Ishigami S, Toda Y, Nakayama H, Fukumoto M,
Fujita J and Imamura M: Clinical significance of vascular
endothelial growth factor and basic fibroblast growth factor gene
expression in liver tumor. Hepatology. 23:455–464. 1996. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Adams J, Huang P and Patrick D: A strategy
for the design of multiplex inhibitors for kinase-mediated
signalling in angiogenesis. Curr Opin Chem Biol. 6:486–492. 2002.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Laird AD and Cherrington JM: Small
molecule tyrosine kinase inhibitors: clinical development of
anticancer agents. Expert Opin Investig Drugs. 12:51–64. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Li W, Liu ML, Cai JH, Tang YX, Zhai LY and
Zhang J: Effect of the combination of a cyclooxygenase-1 selective
inhibitor and taxol on proliferation, apoptosis and angiogenesis of
ovarian cancer in vivo. Oncol Lett. 4:168–174.
2012.PubMed/NCBI
|
|
29
|
Jensen LR, Huuse EM, Bathen TF, Goa PE,
Bofin AM, Pedersen TB, Lundgren S and Gribbestad IS: Assessment of
early docetaxel response in an experimental model of human breast
cancer using DCE-MRI, ex vivo HR MAS, and in vivo 1H
MRS. NMR Biomed. 23:56–65. 2010. View
Article : Google Scholar : PubMed/NCBI
|
|
30
|
Moestue S, Sitter B, Bathen TF, Tessem MB
and Gribbestad IS: HR MAS MR spectroscopy in metabolic
characterization of cancer. Curr Top Med Chem. 11:2–26. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Seierstad T, Røe K, Sitter B, Halgunset J,
Flatmark K, Ree AH, Olsen DR, Gribbestad IS and Bathen TF:
Principal component analysis for the comparison of metabolic
profiles from human rectal cancer biopsies and colorectal
xenografts using high-resolution magic angle spinning 1H
magnetic resonance spectroscopy. Mol Cancer. 7:332008. View Article : Google Scholar
|
